Cogent Biosciences, Inc. (COGT) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $30.82 (-3.55%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 7, 2026 | Michael Yee | UBS | $60.00 | +94.6% |
| Nov 11, 2025 | Chris Raymond | Raymond James | $60.00 | +94.6% |
| Nov 10, 2025 | David Nierengarten | Wedbush | $38.00 | +23.3% |
| Jan 14, 2025 | Robert Burns | H.C. Wainwright | $14.00 | -54.6% |
| Sep 24, 2024 | David Lebowitz | Citigroup | $15.00 | -51.3% |
| Sep 3, 2024 | David Lebowitz | Citigroup | $13.00 | -57.8% |
| Sep 3, 2024 | Robert Burns | H.C. Wainwright | $17.00 | -44.8% |
| Mar 30, 2024 | Kelly Shi | Jefferies | $20.00 | -35.1% |
| Jun 17, 2022 | Chris Raymond | Raymond James | $22.00 | -28.6% |
| Jun 10, 2022 | Christopher Liu | Leerink Partners | $15.00 | -51.3% |
Top Analysts Covering COGT
COGT vs Sector & Market
| Metric | COGT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.41 |
| Analyst Count | 6 | 8 | 19 |
| Target Upside | +67.9% | +153002.0% | +21.5% |
| P/E Ratio | -7.47 | 3.48 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $16M | $16M | $16M | 1 |
| 2027-03-31 | $54M | $54M | $54M | 1 |
| 2027-06-30 | $86M | $86M | $86M | 1 |
| 2027-09-30 | $127M | $127M | $127M | 1 |
| 2027-12-31 | $172M | $172M | $172M | 1 |
| 2028-12-31 | $764M | $764M | $764M | 9 |
| 2029-12-31 | $422M | $1.31B | $2.84B | 4 |
| 2030-12-31 | $564M | $1.75B | $3.79B | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.51 | $-0.51 | $-0.51 | 3 |
| 2027-03-31 | $-0.24 | $-0.24 | $-0.24 | 3 |
| 2027-06-30 | $-0.13 | $-0.13 | $-0.13 | 2 |
| 2027-09-30 | $0.03 | $0.03 | $0.03 | 2 |
| 2027-12-31 | $0.20 | $0.20 | $0.20 | 2 |
| 2028-12-31 | $0.23 | $1.05 | $2.35 | 8 |
| 2029-12-31 | $0.37 | $3.07 | $7.75 | 6 |
| 2030-12-31 | $0.57 | $4.76 | $12.01 | 6 |
Frequently Asked Questions
What is the analyst consensus for COGT?
The consensus among 6 analysts covering Cogent Biosciences, Inc. (COGT) is Buy with an average price target of $51.75.
What is the highest price target for COGT?
The highest price target for COGT is $60.00, set by Michael Yee at UBS on 2026-01-07.
What is the lowest price target for COGT?
The lowest price target for COGT is $13.00, set by David Lebowitz at Citigroup on 2024-09-03.
How many analysts cover COGT?
6 analysts have issued ratings for Cogent Biosciences, Inc. in the past 12 months.
Is COGT a buy or sell right now?
Based on 6 analyst ratings, COGT has a consensus rating of Buy (2.00/5) with a +67.9% upside to the consensus target of $51.75.
What are the earnings estimates for COGT?
Analysts estimate COGT will report EPS of $-0.51 for the period ending 2026-12-31, with revenue estimated at $16M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.